PROGRESS PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PROGRESS PHARMA
Largest movements
- Cash -€44,114
down €44,114 (-70.9%), from €62,222 to €18,108
mainly Contributions, distributions and other (-€40,000) and Net result for the year (-€5,479)
- Contributions -€438,500
down €438,500 (-87.7%), from €500,000 to €61,500
- Profit (loss) carried forward +€393,021
up €393,021 (+96.5%), from -€407,384 to -€14,363
- Trade debts +€1,198
up €1,198 (+83.7%), from €1,432 to €2,630
- Gross operating margin -€2,542
down €2,542 (-108%), from -€2,351 to -€4,893
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €94,048 | €49,934 | -€44,114 | -46.9% |
| Fixed assets | 21/28 | €31,826 | €31,826 | = | 0.0% |
| Financial fixed assets | 28 | €31,826 | €31,826 | = | 0.0% |
| Current assets | 29/58 | €62,222 | €18,108 | -€44,114 | -70.9% |
| Cash at bank and in hand | 54/58 | €62,222 | €18,108 | -€44,114 | -70.9% |
| Total equity and liabilities | 10/49 | €94,048 | €49,934 | -€44,114 | -46.9% |
| Equity | 10/15 | €92,616 | €47,137 | -€45,479 | -49.1% |
| Contributions | 10/11 | €500,000 | €61,500 | -€438,500 | -87.7% |
| Capital | 10 | €500,000 | €61,500 | -€438,500 | -87.7% |
| Issued capital | 100 | €500,000 | €61,500 | -€438,500 | -87.7% |
| Profit (loss) carried forward | 14 | -€407,384 | -€14,363 | +€393,021 | +96.5% |
| Amounts payable | 17/49 | €1,432 | €2,797 | +€1,365 | +95.3% |
| Amounts payable within one year | 42/48 | €1,432 | €2,797 | +€1,365 | +95.3% |
| Trade debts | 44 | €1,432 | €2,630 | +€1,198 | +83.7% |
| Suppliers | 440/4 | €1,432 | €2,630 | +€1,198 | +83.7% |
| Other amounts payable | 47/48 | - | €167 | +€167 | |
| Other operating charges | 640/8 | €505 | €520 | +€14 | +2.8% |
| Gross operating margin | 9900 | -€2,351 | -€4,893 | -€2,542 | -108% |
| Operating profit (loss) | 9901 | -€2,857 | -€5,413 | -€2,556 | -89.5% |
| Financial charges | 65/66B | €65 | €66 | +€2 | +2.3% |
| Recurring financial charges | 65 | €65 | €66 | +€2 | +2.3% |
| Profit (loss) for the period before taxes | 9903 | -€2,921 | -€5,479 | -€2,558 | -87.6% |
| Profit (loss) for the period | 9904 | -€2,921 | -€5,479 | -€2,558 | -87.6% |
| Profit (loss) for the period to be appropriated | 9905 | -€2,921 | -€5,479 | -€2,558 | -87.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 22 October 2026 via checked.be.